488 related articles for article (PubMed ID: 30664164)
21. In vitro and ex vivo anti‑tumor effect and mechanism of Tucatinib in leukemia stem cells and ABCG2‑overexpressing leukemia cells.
Jing W; Zhou M; Chen R; Ye X; Li W; Su X; Luo J; Wang Z; Peng S
Oncol Rep; 2021 Mar; 45(3):1142-1152. PubMed ID: 33650639
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of the PI3K-Akt signaling pathway disrupts ABCG2-rich extracellular vesicles and overcomes multidrug resistance in breast cancer cells.
Goler-Baron V; Sladkevich I; Assaraf YG
Biochem Pharmacol; 2012 May; 83(10):1340-8. PubMed ID: 22342288
[TBL] [Abstract][Full Text] [Related]
23. Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway.
Zhang J; Choi Y; Mavromatis B; Lichtenstein A; Li W
Oncogene; 2003 Sep; 22(40):6289-95. PubMed ID: 13679867
[TBL] [Abstract][Full Text] [Related]
24. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
[TBL] [Abstract][Full Text] [Related]
25. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.
Li C; Liu VW; Chan DW; Yao KM; Ngan HY
Int J Gynecol Cancer; 2012 Jan; 22(1):15-22. PubMed ID: 22080879
[TBL] [Abstract][Full Text] [Related]
26. LY‑294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF‑1α pathway.
Xu R; Zhang Y; Li A; Ma Y; Cai W; Song L; Xie Y; Zhou S; Cao W; Tang X
Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 33982772
[TBL] [Abstract][Full Text] [Related]
27. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis.
Fang J; Ding M; Yang L; Liu LZ; Jiang BH
Cell Signal; 2007 Dec; 19(12):2487-97. PubMed ID: 17826033
[TBL] [Abstract][Full Text] [Related]
28. Timosaponin A-III reverses multi-drug resistance in human chronic myelogenous leukemia K562/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt signaling pathway.
Chen JR; Jia XH; Wang H; Yi YJ; Wang JY; Li YJ
Int J Oncol; 2016 May; 48(5):2063-70. PubMed ID: 26984633
[TBL] [Abstract][Full Text] [Related]
29. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
[TBL] [Abstract][Full Text] [Related]
30. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells.
Martelli AM; Tazzari PL; Tabellini G; Bortul R; Billi AM; Manzoli L; Ruggeri A; Conte R; Cocco L
Leukemia; 2003 Sep; 17(9):1794-805. PubMed ID: 12970779
[TBL] [Abstract][Full Text] [Related]
31. Effect of phosphatase and tensin homology deleted on chromosome 10 (PTEN) gene transfection on reversal of multidrug resistance in K562/ADM cells.
Cheng Z; Yang N; Liang W; Yan X; Li L; Pan L
Leuk Lymphoma; 2012 Jul; 53(7):1383-9. PubMed ID: 22185283
[TBL] [Abstract][Full Text] [Related]
32. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of ATP-Binding Cassette Subfamily G Member 2 Confers Resistance to Phosphatidylinositol 3-Kinase Inhibitor PF-4989216 in Cancer Cells.
Wu CP; Murakami M; Hsiao SH; Chou AW; Li YQ; Huang YH; Hung TH; Ambudkar SV
Mol Pharm; 2017 Jul; 14(7):2368-2377. PubMed ID: 28597653
[TBL] [Abstract][Full Text] [Related]
34. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway.
DeGraffenried LA; Fulcher L; Friedrichs WE; Grünwald V; Ray RB; Hidalgo M
Ann Oncol; 2004 Oct; 15(10):1510-6. PubMed ID: 15367412
[TBL] [Abstract][Full Text] [Related]
35. Reversal effect of PI3-K inhibitor LY294002 on P-glycoprotein-mediated multidrug resistance of human leukemia cell line K562/DNR and gastric cancer cell line SGC7901/ADR.
Zhang Y; Qu XJ; Liu YP; Yang XH; Hou KZ; Teng YE; Zhang JD
Ai Zheng; 2009 Feb; 28(2):97-9. PubMed ID: 19550116
[TBL] [Abstract][Full Text] [Related]
36. PCI29732, a Bruton's Tyrosine Kinase Inhibitor, Enhanced the Efficacy of Conventional Chemotherapeutic Agents in ABCG2-Overexpressing Cancer Cells.
Ge C; Wang F; Cui C; Su X; To KKW; Wang X; Zhang H; Song X; Fu L
Cell Physiol Biochem; 2018; 48(6):2302-2317. PubMed ID: 30114704
[TBL] [Abstract][Full Text] [Related]
37. Abnormal Wnt signaling and overexpression of ABCG2 contributes to drug efflux properties of side population cells in nasopharyngeal carcinoma.
Guan GF; Zhang DJ; Zheng Y; Wen LJ; Yu DJ; Lu YQ; Zhao Y
Mol Med Rep; 2015 Sep; 12(3):4352-4357. PubMed ID: 26081022
[TBL] [Abstract][Full Text] [Related]
38. Bortezomib Is More Effective to Side Population of RPMI8226 Myeloma Cells than Classical Anti-myeloma Agents.
Kim KH; Cheong HJ; Lee MY; Lee N; Lee KT; Park SK; Won JH
Anticancer Res; 2019 Jan; 39(1):127-133. PubMed ID: 30591449
[TBL] [Abstract][Full Text] [Related]
39. PI3K/Akt inhibitor LY294002 potentiates homoharringtonine antimyeloma activity in myeloma cells adhered to stromal cells and in SCID mouse xenograft.
Chen P; Wen X; Wang B; Hou D; Zou H; Yuan Q; Yang H; Xie J; Huang H
Ann Hematol; 2018 May; 97(5):865-875. PubMed ID: 29450644
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine.
Xie X; Tang B; Zhou J; Gao Q; Zhang P
Oncol Rep; 2013 Aug; 30(2):773-82. PubMed ID: 23743572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
